CeQur, a Switzerland-based developer of a wearable, injection-free insulin delivery patch for people living with diabetes, raised $100 million in Series E funding to accelerate its ambitious phase of commercial growth.
Investors were not disclosed.
Including the latest investment round, CeQur has raised close to $500 million in funding to date.
“This financing is a direct reflection of what the CeQur team has built and the confidence our investors have placed in CeQur’s growth trajectory,” said Mike Rubino, Chief Financial Officer of CeQur.
“We are grateful for that trust and committed to deploying this capital to deliver on the full potential of CeQur Simplicity for patients, for providers, and for every investor who believes in our mission,” added Mike Rubino.
CeQur offers a wearable, FDA-cleared insulin patch designed to simplify mealtime (bolus) insulin delivery for adults aged 21 and older.
Last week, CeQur announced that the FDA cleared Simplicity for an extended wear time of up to seven days and gave the green light to a new 1-unit (1U) device.
CeQur began a pilot commercial launch for the FDA-cleared and CE-marked device in early 2021. In April 2021, the company raised $115 million to support that launch and scale manufacturing.
Digital health companies, including wearable device makers, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Osteoboost Health, a developer of FDA-cleared wearable therapy for osteopenia—clinically proven to reduce bone loss in the spine – raised $8 million in a fresh financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of its medical device for low bone density.
In another deal, Click Therapeutics, a developer of AI-based digital therapeutics, raised $50 million in Series D funding from Boehringer Ingelheim, to support the commercialization of its CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.